Poster Session on Novel Therapeutic Targets and Tools

Nathalie Breysse, PhD, Lundbeck - “GPR6 antagonism as a Non-dopaminergic Therapy in Parkinson’s Disease”

Anna Cartier, PhD, ICB International Inc – “Alpha-synuclein SMART Molecule: A Novel Blood-Brain Barrier Permeable Diagnostic Ligand for Parkinson’s Disease”

Robert Friedland, MD, University of Louisville School of Medicine – “The Influence of Bacterial Amyloid on Alpha-synuclein Misfolding in the Rat”

Gregory Gerhardt, PhD, University of Kentucky Medical Center – “Therapeutic Development of siRNA Targeting Alpha-Synuclein”

Val Goodfellow, PhD, Califia Bio, Inc. – “CLFB-1134: MLK3 Inhibition in Pre-clinical Models of PD”

Sok Kean Khoo, PhD, Grand Valley State University – “Circulating microRNAs as Progression Biomarkers for Parkinson’s Disease”

Laurie Mischley, ND, MPH, PhD(c), University of Washington – “Intranasal Glutathione in Parkinson’s Disease”

Adrian Newman-Tancredi, PhD, DSc, Neurolaxis, Inc. – “NLX112, A Novel Candidate for the Treatment of L-DOPA-induced Dyskinesia: Behavioral and Neurochemical Profile in Rat”